calcifediol   Click here for help

GtoPdb Ligand ID: 6921

Synonyms: 25-hydroxyvitamin D3 | calcidiol | Calderol | Ryaldee® | U-32070E
Approved drug PDB Ligand
calcifediol is an approved drug (FDA (2016))
Comment: 25-hydroxyvitamin D3 is the major circulating metabolite of 25-hydroxyvitamin D. Calcifediol is the WHO INN for the same compound.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: calcidiol

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 40.46
Molecular weight 400.33
XLogP 7.93
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC1CCC(=C)C(=CC=C2CCCC3(C2CCC3C(CCCC(O)(C)C)C)C)C1
Isomeric SMILES O[C@H]1CCC(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](CCCC(O)(C)C)C)C)/C1
InChI InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
InChI Key JWUBBDSIWDLEOM-DTOXIADCSA-N
No information available.
Summary of Clinical Use Click here for help
25-hydroxyvitamin D3 is effective in the treatment of rickets and osteomalacia. The US FDA originally approved this nutraceutical in 1980, but use was discontinued.
In June 2016, the FDA approved the Rayaldee® extended release formulation of calcifediol as the first treatment for patients with hyperparathyroidism secondary to chronic kidney disease (e.g. predialysis patients). Rayaldee® is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Activates the transcriptional activity of the vitamin D receptor which eventually leads to increased serum calcium levels.